首頁 > 市場調查報告書 > 醫療設備

電子醫療設備

市場調查報告書

商品編碼

1575740

全球經顱直流電刺激市場 - 2024-2031

Global Transcranial Direct Current Stimulation Market - 2024-2031

出版日期: 2024年10月22日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

2023年，全球經顱直流電刺激市場規模達13.4613億美元，預計2031年將達到27.4188億美元，2024-2031年預測期間複合年成長率為9.3%。

經顱直流電刺激 (tDCS) 是一種非侵入性腦刺激技術，涉及透過電極向頭皮施加低電流。通常，該電流範圍為 1 至 2 mA。 tDCS 透過傳遞正（陽極）或負（陰極）電流來調節目標大腦區域的神經元活動。這些電極的位置決定了電流的流動方式，從而刺激大腦的特定區域。

tDCS 的機制不涉及神經元產生動作電位；相反，它會產生“亞閾值”效應，增強或抑制已經活躍的神經元的活動。這可以被概念化為 tDCS 促進與任務或學習過程相關的持續大腦活動。在細胞層面上，tDCS 會影響神經元放電並增強突觸傳遞，從而促進突觸可塑性，這對於學習至關重要。

tDCS 經常與訓練活動結合使用，其中刺激會放大訓練本身產生的學習效果。正在探索的 tDCS 臨床應用包括治療憂鬱症、精神分裂症、失語症、成癮、癲癇、慢性疼痛（包括偏頭痛和纖維肌痛）、注意力障礙和運動復健等疾病。除了醫療用途之外，經顱直流電刺激 (tDCS) 也應用於非臨床環境，例如加速學習、提高注意力、放鬆和冥想。

市場動態：

司機

神經和精神疾病盛行率不斷增加

全球經顱直流電刺激（tDCS）市場的需求是由多種因素所驅動的。關鍵因素之一是神經和精神疾病的盛行率不斷增加。憂鬱、焦慮、慢性疼痛和認知障礙等心理健康問題的發生率不斷上升，極大地影響了經顱直流電刺激 (tDCS) 市場的擴張。 tDCS 是一種非侵入性腦刺激方法，可將溫和的電流傳送到頭皮的目標區域，旨在影響神經元活動並增強神經可塑性。

tDCS 透過改變大腦特定區域神經元的興奮性來發揮作用。當施加陽極（正）刺激時，它可以增加神經元的興奮性，而陰極（負）刺激可以降低神經元的興奮性。這種調節可以導致大腦功能發生變化，有利於治療一系列精神和神經系統疾病。《柳葉刀神經病學》發表的一項重要研究顯示，截至 2021 年，全球有超過 30 億人受到神經系統疾病的影響，佔全球人口的 43% 以上。

此外，行業研究活動、技術進步和產品批准的關鍵參與者將推動該市場的成長。例如，根據2024 年1 月HCPLive 新聞報道，最近的一項研究發現，對於個人而言，家用經顱直流電刺激(tDCS) 與數位心理干預或數位安慰劑相結合時，並未表現出優於假治療的優越性。這項結論來自一項結構良好的臨床試驗，旨在評估這些干預措施的功效。

此外，在 2024 年 1 月的《歐洲醫療保健》研究出版物中，自我管理的大腦刺激，特別是透過顱內直流電刺激 (tDCS)，正在成為治療憂鬱症的一種新工具。這種方法允許患者在家中管理他們的治療，可能增加重度憂鬱症 (MDD) 患者的可近性和便利性。

同樣，2022 年 5 月，Flow Neuroscience 宣布已獲得美國食品藥物管理局 (FDA) 的完全研究設備豁免 (IDE) 批准，可使用其自我管理經顱直流電刺激在美國進行一項關鍵試驗。耳機，用於治療重度憂鬱症（MDD）。這標誌著他們在使憂鬱症患者更容易獲得創新的腦刺激技術方面邁出了重要一步。

限制

監管挑戰、替代神經調節技術的存在以及個人缺乏意識等因素預計將阻礙市場的發展。

細分市場分析

全球經顱直流電刺激 (tDCS) 市場根據設備類型、應用、最終用戶和地區進行細分。

1*1 tDCS平台部分約佔全球經顱直流電刺激（tDCS）市場佔有率的46.8%

1*1 tDCS 平台領域預計將在預測期內佔據最大的市場佔有率。 Soterix Medical 開發的 1x1 tDCS 平台是經顱直流電刺激 (tDCS) 市場的領先設備，以其精度、可靠性和客製化能力而聞名。該平台專為臨床和研究應用而設計，提供一系列獨特的功能，使其有別於其他設備。

該平台具有開放式面板介面，可簡化設定過程並促進對刺激設定的直接監控。此外，它還採用了 SmartSCAN 等先進技術，可即時監控電極接觸，而 TrueCurrent 可確保整個刺激過程中電流傳輸的一致性。

Soterix Medical 1x1 tDCS 設備代表了經顱直流電刺激 (tDCS) 領域的重大進步，專為臨床研究和治療應用而設計。 1x1 平台由臨床研究人員、科學家和生物醫學工程師團隊開發，因其在提供 tDCS 協議方面的精度和可靠性而受到認可。

Soterix Medical 1x1 tDCS 設備被認為是神經調節領域的首要解決方案，特別是針對旨在解決憂鬱症等心理健康問題的研究和臨床應用。其設計將使用者友善的功能與先進的技術和適應性相結合，使其成為希望研究 tDCS 治療效果同時確保研究安全性和一致性的研究人員的必備工具。因此，它已成為臨床試驗中準確且可重複的 tDCS 的基準，有助於推動腦部刺激療法知識的進步。

市場地理分析

北美約佔全球經顱直流電刺激（tDCS）市場佔有率的43.2%

由於憂鬱、焦慮和慢性疼痛等神經和精神疾病的盛行率不斷上升，北美地區預計將在預測期內佔據最大的市場佔有率，這是推動經顱直流電刺激擴張的主要因素。

醫療保健專業人員和患者對非侵入性治療方案的認可和接受程度越來越高。這一趨勢推動了 tDCS 設備在臨床環境中的採用，作為傳統藥物療法的可行替代方案。此外，在該地區，大量關鍵參與者的存在、先進的醫療保健基礎設施、對家用設備不斷成長的需求、創新技術進步、政府舉措以及正在進行的研究、產品發布和批准將推動該市場的成長。

例如，2022 年 4 月，佛羅裡達州立大學護理學院成立了腦科學和症狀管理中心 (BSSMC)，該機構專注於跨學科研究，利用腦部刺激和電腦技術最佳化疼痛和症狀管理。該中心由 Hyochol "Brian" Ahn 博士領導，他獲得了美國國立衛生研究院 (NIH) 的大量資助，探索使用經顱直流電刺激 (tDCS) 與基於正念的冥想相結合進行自我管理患有膝骨關節炎的老年人的臨床疼痛和症狀。

此外，2023 年 3 月，Sooma Medical 因其旨在治療憂鬱症的攜帶式、患者管理的神經調節設備獲得了美國食品和藥物管理局 (FDA) 的突破性設備認定。該頭銜授予那些在改善嚴重或危及生命疾病的治療選擇方面表現出巨大潛力的創新療法。

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low electric current to the scalp through electrodes. Typically, this current ranges from 1 to 2 mA. tDCS operates by delivering either a positive (anodal) or negative (cathodal) current, which modulates neuronal activity in targeted brain regions. The positioning of these electrodes determines how the current flows, allowing for specific areas of the brain to be stimulated.

The mechanism of tDCS does not involve generating action potentials in neurons; instead, it produces "sub-threshold" effects that enhance or inhibit the activity of already active neurons. This can be conceptualized as tDCS boosting ongoing brain activity related to tasks or learning processes. At the cellular level, tDCS influences neuronal firing and enhances synaptic transmission, thereby promoting synaptic plasticity, which is essential for learning.

tDCS is frequently utilized in conjunction with training activities, where the stimulation amplifies the learning effects produced by the training itself. Clinical applications being explored for tDCS include treatment for conditions such as depression, schizophrenia, aphasia, addiction, epilepsy, chronic pain (including migraines and fibromyalgia), attention disorders, and motor rehabilitation. Beyond medical uses, tDCS is also applied in non-clinical settings for purposes like accelerated learning, improved focus, relaxation, and meditation.

Market Dynamics: Drivers

Increasing prevalence of neurological and psychiatric disorders

The demand for the global transcranial direct current stimulation (tDCS) market is driven by multiple factors. One of the key factors is the increasing prevalence of neurological and psychiatric disorders. The rising rates of mental health issues, including depression, anxiety, chronic pain, and cognitive impairments, have greatly impacted the expansion of the transcranial direct current stimulation (tDCS) market. tDCS is a non-invasive brain stimulation method that delivers a mild electrical current to targeted regions of the scalp, intending to influence neuronal activity and enhance neuroplasticity.

tDCS operates by modifying the excitability of neurons in specific areas of the brain. When anodal (positive) stimulation is applied, it can increase neuronal excitability, whereas cathodal (negative) stimulation can decrease it. This modulation can result in functional changes in the brain that are advantageous for treating a range of psychiatric and neurological conditions. A significant study published in the Lancet Neurology revealed that as of 2021, more than 3 billion individuals globally were affected by neurological conditions, which account for over 43% of the world's population.

Moreover, key players in the industry research activities, technological advancements, and product approvals would drive this market growth. For instance, as per HCPLive news in January 2024, a recent study has found that home-use transcranial direct current stimulation (tDCS), when combined with either a digital psychological intervention or a digital placebo, does not demonstrate superiority over sham treatment for individuals experiencing a major depressive episode. This conclusion comes from a well-structured clinical trial designed to assess the efficacy of these interventions.

Also, in a Healthcare Europe research publication in January 2024, self-administered brain stimulation, particularly through transcranial direct current stimulation (tDCS), is emerging as a novel tool for treating depression. This approach allows patients to manage their treatment at home, potentially increasing accessibility and convenience for those suffering from major depressive disorder (MDD).

Similarly, in May 2022, Flow Neuroscience announced that it had received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to conduct a pivotal trial in the United States using its self-managed transcranial direct current stimulation (tDCS) headset for the treatment of Major Depressive Disorder (MDD). This marks a significant step in making their innovative brain stimulation technology more accessible to patients suffering from depression.

Restraints

Factors such as regulatory challenges, the presence of alternative neuromodulation techniques, and lack of awareness among individuals are expected to hamper the market.

Market Segment Analysis

The global transcranial direct current stimulation (tDCS) market is segmented based on device type, application, end-user, and region.

The 1x1 tDCS platform segment accounted for approximately 46.8% of the global transcranial direct current stimulation (tDCS) market share

The 1x1 tDCS platform segment is expected to hold the largest market share over the forecast period. The 1x1 tDCS platform developed by Soterix Medical is a leading device in the transcranial direct current stimulation (tDCS) market, known for its precision, reliability, and customization capabilities. This platform is designed for both clinical and research applications, offering a range of unique features that set it apart from other devices.

The platform features an Open-Panel interface that streamlines the setup process and facilitates straightforward monitoring of stimulation settings. Additionally, it utilizes advanced technologies like SmartSCAN, which provides real-time monitoring of electrode contact, and TrueCurrent, which guarantees consistent current delivery during the entire stimulation session.

The Soterix Medical 1x1 tDCS device represents a significant advancement in the field of transcranial direct current stimulation (tDCS), designed specifically for clinical research and therapeutic applications. Developed by a team of clinical researchers, scientists, and biomedical engineers, the 1x1 platform is recognized for its precision and reliability in delivering tDCS protocols.

The Soterix Medical 1x1 tDCS device is recognized as a premier solution in the neuromodulation field, particularly for research and clinical applications aimed at addressing mental health issues such as depression. Its design combines user-friendly features with advanced technology and adaptability, making it an essential instrument for researchers who wish to investigate the therapeutic benefits of tDCS while ensuring safety and consistency in their studies. Consequently, it has established itself as the benchmark for accurate and reproducible tDCS in clinical trials, contributing to the advancement of knowledge regarding brain stimulation therapies.

Market Geographical Analysis

North America accounted for approximately 43.2% of the global transcranial direct current stimulation (tDCS) market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of neurological and psychiatric disorders, including depression, anxiety, and chronic pain, which is a major factor driving the expansion of the transcranial direct current stimulation (tDCS) market.

There is an increasing recognition and acceptance of non-invasive treatment options among healthcare professionals and patients alike. This trend is fueling the adoption of tDCS devices in clinical settings as a viable alternative to conventional pharmacological therapies. Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, rising demand for home-use devices, innovative technological advancements, government initiatives, and ongoing research studies, product launches & approvals would propel this market growth.

For instance, in April 2022, the Florida State University College of Nursing launched the Brain Science and Symptom Management Center (BSSMC), an institute focused on interdisciplinary research to optimize pain and symptom management using brain stimulation and computer technology. The center is led by Dr. Hyochol "Brian" Ahn, who has received significant funding from the National Institutes of Health (NIH) to explore the use of transcranial direct current stimulation (tDCS) in combination with mindfulness-based meditation for self-management of clinical pain and symptoms in older adults with knee osteoarthritis.

Also, in March 2023, Sooma Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its portable, patient-administered neuromodulation device aimed at treating depression. This designation is granted to innovative therapies that show significant potential to improve treatment options for severe or life-threatening conditions.

Market Segmentation

By Device Type

Depression LTE System

1x1 tDCS Platform

Thebraindriver v2.1 Deluxe System

DC-Stimulator Mobile

Nurostym Transcranial Electrical Stimulation (tES)

Others

By Application

Depression

Anxiety

Chronic Pain

Cognitive Impairments

By End-User

Hospitals & Home Use

Neurological Clinics

Ambulatory Surgical Centers

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the transcranial direct current stimulation (tDCS) market include Soterix Medical Inc., TheBrainDriver, LLC., Neurocare group AG, Brainbox Ltd, BrainsWay, Magstim, eNeura Inc., MagVenture A/S, Nexalin Technology, and RPW Technology, LLC among others.

Key Developments

In September 2024, the medical-grade neurotechnology wearable for premenstrual syndrome (PMS) refers to an innovative device designed to provide a drug-free solution for managing PMS and menstrual pain. This wearable, developed by the startup Samphire Neuroscience and named Nettle, utilizes transcranial direct current stimulation (tDCS) to target specific areas of the brain associated with mood regulation and pain perception.

In April 2024, Neurovalens, a Belfast-based neurotech startup, received FDA clearance for its Modius Stress device, a non-invasive home-use neurostimulation system designed to treat generalized anxiety disorder (GAD).

Why Purchase the Report?

To visualize the global transcranial direct current stimulation (tDCS) market segmentation based on device type, application, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points on the transcranial direct current stimulation (tDCS) market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel with key products of all the major players.

The global transcranial direct current stimulation (tDCS) market report would provide approximately 62 tables, 57 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Neurological and Psychiatric Disorders
- 4.1.2. Restraints
  - 4.1.2.1. Regulatory Challenges
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Device Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 6.1.2. Market Attractiveness Index, By Device Type
6.2. Depression LTE System *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. 1x1 tDCS Platform
6.4. Thebraindriver v2.1 Deluxe System
6.5. DC-Stimulator Mobile
6.6. Nurostym Transcranial Electrical Stimulation (tES)
6.7. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Depression *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Anxiety
7.4. Chronic Pain
7.5. Cognitive Impairments

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Hospitals & Home Use *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurological Clinics
8.4. Ambulatory Surgical Centers
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Soterix Medical Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. TheBrainDriver, LLC.
11.3. Neurocare Group AG
11.4. Brainbox Ltd.
11.5. BrainsWay
11.6. Magstim
11.7. eNeura Inc.
11.8. MagVenture A/S
11.9. Nexalin Technology
11.10. RPW Technology, LLC (*LIST NOT EXHAUSTIVE)